Clinical trials: HPV Infections
Human Papilloma Virus (HPV), Cervical Carcinoma
Transmission of Oncogenic HPV Infection Among Families
The goal of the Transmission of Oncogenic HPV Infection Among Families (TREVINO) study is to improve understanding of how high-risk human papillomavirus (HPV) infections are transmitted within families.
- Conditions
- Human Papilloma Virus (HPV), Cervical Carcinoma, Oropharyngeal Carcinoma, Transmission Vertical
- Trial name
- TREVINO (NCT07036211)
- Where
- 2 sites in Finland
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Tampere University Hospital
HPV Infections
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
This study is designed to determine the tolerability and immunogenicity of a 3-dose regimen of Gardasil administered to healthy married females between 16 and 23 years of age, in India.
- Trial name
- NCT00733122
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV - Anogenital Human Papilloma Virus Infection, HIV Infections
Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study)
Phase IV prospective study measuring the immunogenicity (neutralizing antibody titles against each HPV vaccine genotype) of the 9-valent vaccine against HPV (Gardasil9®Merck) in HIV-positive women aged 15-40 years with fully…
- Trial name
- Papillon (NCT03391921)
- Testing
- Vaccine
- Where
- Belgium
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Safety Issues, HPV Infection
BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects
This is a follow-up study for patients treated with FluBHPVE6E7 in previous interventional studies.
- Trial name
- NCT04528407
- Testing
- Observation without intervention
- Where
- Austria
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- BlueSky Immunotherapies GmbH
HPV Infection, HPV-Related Carcinoma
A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
To evaluate the safety and tolerability of 15-valent HPV vaccine in 9-45year-old participants.
- Conditions
- HPV Infection, HPV-Related Carcinoma, Genital Wart, HPV-Related Intraepithelial Neoplasia
- Trial name
- NCT06454175
- Testing
- 15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha)
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Human Papilloma Virus (HPV) Vaccine
Knowledge, Attitude &Practice on Human Papilloma Virus Vaccination Among Healthcare Providers and General Population
Cervical cancer is caused by persistent infection with certain strains of the human papillomavirus (HPV), which is a very common virus transmitted through sexual activity.
- Trial name
- NCT06743880
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Assiut University
Cervical Intraepithelial Neoplasia, HPV Infection
Effect of HPV Integration on Prognosis of Young Women With CIN2 in China
Clinically, cervical precancerous lesion is one of the important diseases that endanger the life safety and fertility of young women.
- Conditions
- Cervical Intraepithelial Neoplasia, HPV Infection, Virus Integration, HSIL, High Grade Squamous Intraepithelial Lesions
- Trial name
- NCT05282095
- Testing
- Follow up
- Where
- 20 sites in China
- Volunteers
- 300 people
- Sponsor
- Fujian Maternity and Child Health Hospital
HPV Infection, Health Behavior
HPV Vaccination Health-promotion Programme on Vaccine Acceptance and Uptake Among Female Adolescents
The MDL-SHPVP will be developed and a clustered randomised controlled trial will be conducted to evaluate the effects of the MDL-SHPVP and to examine whether the effect of the MDL-SHPVP on the rate of HPV vaccine uptake 1 year…
- Conditions
- HPV Infection, Health Behavior, Health Attitude
- Trial name
- NCT04438291
- Testing
- MDL-SHPVP, 30-minute educational video
- Where
- Hong Kong
- Volunteers
- 1,340 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
HPV Infection, Preventive Health Services
PCOM2 - The Physician Communication Intervention, Version 2.0
Poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for HPV-associated cancers and diseases.
- Trial name
- PCOM2 (NCT05336240)
- Testing
- Physician Communication 2 Virtual (PCOM2-virtual), Physician Communication Standard (PCOM-standard)
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Colorado, Denver
Cancer of Cervix, HPV Infection
The Effect of Education Given to Women on Cervical Cancer on Knowledge, Attitude and Belief
Aim: The aim of this study is to reveal the effect of education given to women about cervical cancer on knowledge, attitude and belief.
- Trial name
- EEWCCKAB (NCT05990270)
- Testing
- education
- Where
- Turkey (Türkiye)
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Kahramanmaras Sutcu Imam University
HPV Infections, Cervical Cancer
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese females aged 9 to 45 years
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT04895020
- Testing
- 9-valent HPV vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
HPV Infections, Cervical Cancer Stage IIa
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05027776
- Testing
- 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years
- Where
- China
- Volunteers
- 1,348 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
HPV Infections, Cervical Cancer Stage IIa
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05371353
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
HPV Infection, HPV Vaccination
Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents
The risk for Human Papillomavirus (HPV) infection persists through an individual sexual life and duration of protection is critical to vaccine effectiveness in protection from oncogenic hrHPV infection.
- Trial name
- NCT05435209
- Testing
- Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
- Where
- Kenya
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- University of Washington
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
HPV Infection, LSIL, Low-Grade Squamous Intraepithelial Lesions
Research About Impact of HPV Integration on the Prognosis of Women With Persistent HR-HPV Infection
Clinically, patients with persistent HR-HPV infection for more than 18 months or HR-HPV infection with CIN2 + need regular colposcopic biopsy to assess the outcome and progression of the disease.
- Conditions
- HPV Infection, LSIL, Low-Grade Squamous Intraepithelial Lesions, HSIL, High-Grade Squamous Intraepithelial Lesions, Virus Integration
- Trial name
- NCT05283239
- Testing
- Follow up
- Where
- 11 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Fujian Maternity and Child Health Hospital
HPV Infection, HPV Vaccine
Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity
This is a multi-center, open, prospective cohort study that aims to investigate the immunogenicity and immune persistence of two different domestically produced bivalent HPV vaccines compared with an imported HPV vaccine in women…
- Conditions
- HPV Infection, HPV Vaccine, Cervical Cancer Prevention
- Trial name
- NCT06137352
- Testing
- Follow up
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fujian Maternity and Child Health Hospital
Conscripts, Military Induction Board
Prevalence of ENT Diseseas
The aim of the present study will be to evaluate in conscripts at the military induction board the prevalence of rhinosinusitis, the prevalence of HPV vaccinations, the prevalence of hearing impairments and the prevalence of…
- Conditions
- Conscripts, Military Induction Board, ENT Disease, Rhinosinusitis Chronic
- Trial name
- PrENT (NCT06105346)
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
HPV Infections
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9…
- Trial name
- NCT03900572
- Testing
- HPV Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
HPV Infection
Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females
The purpose of this study is to evaluate the immunogenicity and safety of three consecutive lots of bivalent HPV (Type 16,18) vaccine (Pichia pastoris) in healthy female subjects aged 9 - 30 years, and demonstrate the…
- Trial name
- NCT04965350
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd